MEDIFAST INC
Long
업데이트됨

$MED Oversold and Due For A Bounce

373
MED is now extremely oversold with an RSI just above 20. After missing earnings last Friday, what's notable is that traders did buy the dip and we got a green candle on the day. We believe this is a sign that MED is now too cheap to ignore. MED is now trading at just 12x earnings and a PEG of 0.62.

Medifast (NYSE:MED) closed down 27% on the heels of its Q3 report. Highlights:

Revenue: $190.1M (+36.5%).

Net income: $15.9M (+15.4%); EPS: $1.32 (+15.8%).

Q4 guidance: Revenue: $157M - 167M; EPS: $1.03 - 1.13.

2019 guidance: Revenue: $700M - 710M from $730M - 750M; EPS: $5.80 - 5.90 from $6.75 - 6.95. Guidance revised due to "short-term challenges."

Medifast, Inc., through its subsidiaries, manufactures and distributes weight loss, weight management, healthy living products, and other consumable health and nutritional products. It offers bars, bites, pretzels, puffs, oatmeal and cereal crunch products, drinks, hearty choices, pancakes, puddings, soft serves, shakes, smoothies, soft bakes, and soups under the Medifast, OPTAVIA, Thrive by Medifast, Optimal Health by OPTAVIA, Flavors of Home, and Essential 1 brands. The company sells its products through various channels, including the Internet, call centers, independent health advisors, franchise weight loss clinics, and direct consumer marketing. The company was founded in 1980 and is headquartered in Baltimore, Maryland.

As always, trade with caution and use protective stops.

Good luck to all!
거래청산: 타겟 닿음
MED up 38% in just 5 weeks since we recommended it to our subscribers.

Congrats to all who participated!

면책사항

해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.